These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3220080)

  • 1. Adjuvant effects of prostaglandin D2 to cisplatin on human ovarian cancer cell growth in nude mice.
    Kikuchi Y; Miyauchi M; Iwano I; Kita T; Oomori K; Kizawa I
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1829-33. PubMed ID: 3220080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic values of prostaglandin D2 in nude mice bearing human ovarian carcinoma].
    Kikuchi Y; Miyauchi M; Nagata I
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):121-8. PubMed ID: 2313142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells.
    Kikuchi Y; Kita T; Miyauchi M; Hirata J; Sasa H; Nagata I; Fukushima M
    J Cancer Res Clin Oncol; 1992; 118(6):453-7. PubMed ID: 1618893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2.
    Kikuchi Y; Miyauchi M; Oomori K; Kita T; Kizawa I; Kato K
    Cancer Res; 1986 Jul; 46(7):3364-6. PubMed ID: 3458525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antineoplastic effects of cisplatin by a calmodulin antagonist (W-7) in nude mice bearing human ovarian carcinoma.
    Oomori K; Kikuchi Y; Kita T; Iwano I; Kizawa I; Kato K
    Cancer Detect Prev; 1988; 12(1-6):481-6. PubMed ID: 3180142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma.
    Kikuchi Y; Oomori K; Kizawa I; Hirata J; Kita T; Miyauchi M; Kato K
    Cancer Res; 1987 Dec; 47(24 Pt 1):6459-61. PubMed ID: 3677086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Potentiation of the antitumor effect of cisplatin by calmodulin antagonists (W-7 and W-5) in nude mice bearing human ovarian carcinoma].
    Kikuchi Y; Oomori K; Kizawa I; Kita T; Miyauchi M; Iwano I; Kato K
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jan; 40(1):81-6. PubMed ID: 3351366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
    Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
    Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin.
    Adachi T; Mano H; Shinohara Y; Nakanishi T; Suzuki T; Ino K; Kato N; Okamoto T; Nawa A; Goto S
    Cancer Immunol Immunother; 1993 Jul; 37(1):1-6. PubMed ID: 8513448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice].
    Ishii K; Kita T; Hirata J; Tode T; Kikuchi Y; Nagata I
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Apr; 45(4):333-9. PubMed ID: 8509669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.
    Li W; Wan L; Zhai LY; Wang J
    Int J Mol Sci; 2014 Oct; 15(10):19265-80. PubMed ID: 25342321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo.
    Kikuchi Y; Sasa H; Kita T; Hirata J; Tode T; Nagata I
    Anticancer Drugs; 1991 Feb; 2(1):63-7. PubMed ID: 1958854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis.
    Anderson K; Lawson KA; Simmons-Menchaca M; Sun L; Sanders BG; Kline K
    Exp Biol Med (Maywood); 2004 Dec; 229(11):1169-76. PubMed ID: 15564444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-inhibitory effects of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl combined with cisplatin on human ovarian cancer cells inoculated into nude mice.
    Hiramatsu H; Kikuchi Y; Kudoh K; Kita T; Tode T; Nagata I
    Jpn J Cancer Res; 1997 Oct; 88(10):1003-8. PubMed ID: 9414663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of granulocyte-colony-stimulating factor and interleukin-2 on ascites formation and the survival time of nude mice bearing human ovarian cancer cells.
    Kikuchi Y; Imaizumi E; Kataoka Y; Hirata J; Kita T; Tode T; Nagata I
    Cancer Immunol Immunother; 1996 Dec; 43(5):257-61. PubMed ID: 9024501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
    Kikuchi Y; Oomori K; Iwano I; Kizawa I; Miyauchi M; Kita T; Kuki E
    Gynecol Oncol; 1989 Nov; 35(2):172-6. PubMed ID: 2509301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitory effects of oral administration of ginsenoside Rh2 on tumor growth in nude mice bearing serous cyst adenocarcinoma of the human ovary].
    Tode T; Kikuchi Y; Hirata J; Kita T; Imaizumi E; Nagata I
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Nov; 45(11):1275-82. PubMed ID: 8258727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.